Gene expression profiles in lung cancer using cDNA rrays

基因表达序列分析(SAGE)是一种高度定量的方法，它确定了存在于任何特定感兴趣组织中的每个转录本的相对表达。我们最近使用分层聚类和我们的SAGE结果对肺癌的基因表达进行了全面的分析。我们发现，根据SAGE鉴定的基因表达模式，可以区分肿瘤状态以及癌症亚型。此外，我们确定了115个高度差异表达的转录本，这些转录本也可以提供相同的区别。这些基因中的许多要么以前被确定为肺肿瘤标记物，要么揭示了所分析的肿瘤组织特有的分子特征。 基因芯片是一种补充方法，允许快速分析许多存在于组织中较高水平的基因。利用Affymetrix基因芯片，我们观察了50个原发肺肿瘤，以确定这些肿瘤中的基因表达模式。目前正在进行分析，以确定通过基因阵列获得的基因表达模式与肺癌的临床和遗传表型之间的关联。我们的阵列数据还表明，参与G1/S和细胞凋亡途径的基因在肺癌组织中经常过度表达。 在过去的一年里，我们还构建了一个包含300例肿瘤组织的肺组织微阵列。我们正在扩展我们的研究，包括免疫组织化学分析，以确定不同生物途径和临床结果中蛋白质的相互作用。 我们还开始研究早发和晚发肺癌患者肿瘤之间的基因表达和遗传差异。

Serial analysis of gene expression (SAGE) is a highly quantitative method that determines the relative expression of each transcript present in any particular tissue of interest. We have recently performed a comprehensive analysis of gene expression using hierarchical clustering and our SAGE result from lung cancers. We found that the neoplastic state as well as the cancer subtypes could be distinguished based on gene expression patterns identified by SAGE. Furthermore, we identified 115 highly differentially expressed transcripts that could also provide the same distinction. Many of these genes were either previously identified as lung tumor markers or revealed molecular characteristics unique to the tumor tissue analyzed. cDNA array is a complementing method that allows for rapid analysis of many genes that are present at a higher level in the tissues. Using Affymetrix cDNA arrays, we have surveyed 50 primary lung tumors to determine the gene expression pattern among these tumors. Analysis are currently underway to determine the association of gene expression patterns obtained by cDNA array with the clinical and genetic phenotypes of lung cancer. Our array data also suggests that genes involved in G1/S and apoptosis pathways are frequently over expression in lung tumor tissues. During the past year, we have also constructed a lung tissue microarray that contains tumor tissues from 300 cases. We are expanding our study to include immunohistochemistry analysis to determine the interaction of proteins in different biological pathways and clinical outcome. We have also began to investigate the gene expression as well as genetic differences between the tumors in early and late onset lung cancer patients.